BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Epirubicin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Epirubicin\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04290793-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Epirubicin: Phase 2/3 readout est. (NCT04290793)
DESCRIPTION:Epirubicin\, phase 2/3\, Breast Cancer.\nStudy: Neoadjuvant Che
 motherapy With Pyrotinib\, Epirubicin and Cyclophosphamide Followed by Tax
 anes and Trastuzumab for HER-2+ Breast Cancer\nEstimated primary completio
 n: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 pirubicin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04290793
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699576-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Epirubicin: Phase 1 readout est. (NCT06699576)
DESCRIPTION:Epirubicin\, phase 1.\nStudy: ARTEMIS-103: Phase 1b Study of HS
 -20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.\nEstima
 ted primary completion: 30 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06699576
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05978648-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT05978648)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Trilaciclib in Pa
 tients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemo
 therapy\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05978648
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05024734-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT05024734)
DESCRIPTION:Epirubicin\, phase 2.\nStudy: Guiding Instillation in Non Muscl
 e-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoi
 ds\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05024734
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771871-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epirubicin: Phase 2 readout est. (NCT04771871)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: MicroRNA Profiles
  in Triple Negative Breast Cancer\nEstimated primary completion: March 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04771871
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02455141-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epirubicin: Phase 3 readout est. (NCT02455141)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: Adjuvant Treatmen
 t of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cance
 r\nEstimated primary completion: March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02455141
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900206-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Epirubicin: Phase 2 readout est. (NCT05900206)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cance
 r\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05900206
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05420454-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Epirubicin: Phase 4 readout est. (NCT05420454)
DESCRIPTION:Epirubicin\, phase 4\, Breast Cancer.\nStudy: A Study for the N
 eoadjuvant Treatment of Breast Cancer\nEstimated primary completion: 10 Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05420
 454
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05420467-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Epirubicin: Phase 4 readout est. (NCT05420467)
DESCRIPTION:Epirubicin\, phase 4\, Breast Cancer.\nStudy: A Study for the A
 djuvant Treatment of Breast Cancer\nEstimated primary completion: 10 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05420467
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739485-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Epirubicin: Phase 1/2 readout est. (NCT07739485)
DESCRIPTION:Epirubicin\, phase 1/2\, Breast Cancer.\nStudy: Paclitaxel Oral
  Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Fin
 ding Study\nEstimated primary completion: 30 July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07739485
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287308-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epirubicin: Phase na readout est. (NCT05287308)
DESCRIPTION:Epirubicin\, phase na\, Breast Cancer.\nStudy: Adjuvant Albumin
 -bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study\nEst
 imated primary completion: September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05287308
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678933-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Epirubicin: Phase 3 readout est. (NCT05678933)
DESCRIPTION:Epirubicin\, phase 3.\nStudy: AC-CHOP Versus CHOP in Patients W
 ith Previously Untreated PTCL-TFH\nEstimated primary completion: 1 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT056789
 33
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320508-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20271212
DTEND;VALUE=DATE:20271213
SUMMARY:Epirubicin: Phase 2 readout est. (NCT07320508)
DESCRIPTION:Epirubicin\, phase 2.\nStudy: Epirubicin Interventional Chemoth
 erapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study\
 nEstimated primary completion: 12 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07320508
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Epirubicin\, phase 2.\nStudy: Study of Precision Treatment for 
 Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ep
 irubicin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06692491
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Fudan University 
 Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoa
 djuvant Therapy\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06964906-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06964906)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant High-
 Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemothe
 rapy for ER-Positive /HER2-Negative Breast Cancer\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/epirubicin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06964906
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03286634-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epirubicin: Phase 2 readout est. (NCT03286634)
DESCRIPTION:Epirubicin\, phase 2.\nStudy: ASIA Down Syndrome Acute Lymphobl
 astic Leukemia 2016\nEstimated primary completion: 31 March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03286634
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860529-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06860529)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Serplulimab Combi
 ned With Chemotherapy for Early-stage HR+/HER2- Breast Cancer\nEstimated p
 rimary completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/epirubicin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06860529
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616141-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Epirubicin: Phase 2 readout est. (NCT07616141)
DESCRIPTION:Epirubicin\, phase 2.\nStudy: Neoadjuvant Anlotinib and Epirubi
 cin for T4 Sinonasal Adenoid Cystic Carcinoma\nEstimated primary completio
 n: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epiru
 bicin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07616141
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900516-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Epirubicin: Phase 2 readout est. (NCT07900516)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: A Prospective\, P
 hase II\, Exploratory Study Protocol of a Chemotherapy Sensitivity-based C
 ulmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breas
 t Cancer.\nEstimated primary completion: 1 August 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07900516
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753642-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Epirubicin: Phase 2 readout est. (NCT07753642)
DESCRIPTION:Epirubicin\, phase 2.\nStudy: Golidocitinib Plus Anthracycline-
 based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma\
 nEstimated primary completion: 31 August 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07753642
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016399-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Epirubicin: Phase 2 readout est. (NCT07016399)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Darol
 utamide Alone or in Combination With Standard Therapy for Stage II-IIIA\, 
 AR+\, TNBC\nEstimated primary completion: 1 September 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07016399
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522879-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Epirubicin: Phase 2 readout est. (NCT07522879)
DESCRIPTION:Epirubicin\, phase 2.\nStudy: A Study of Becotatug Vedotin (MRG
 003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive\, U
 nresectable Recurrent Sinonasal Adenoid Cystic Carcinoma\nEstimated primar
 y completion: 1 October 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/epirubicin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07522879
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Epirubicin: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: A Phase III Rando
 mised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant T
 reatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast C
 ancer\nEstimated primary completion: 20 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06291064-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06291064)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Trial Studying Ch
 emotherapy in Nigerian Women With Triple Negative Breast Cancer\nEstimated
  primary completion: June 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/epirubicin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06291064
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Epirubicin\, phase 2\, Breast Cancer.\nStudy: Study of Patritum
 ab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participa
 nts With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Pos
 itive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\nEst
 imated primary completion: 31 December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/epirubicin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227065-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Epirubicin: Phase 2 readout est. (NCT06227065)
DESCRIPTION:Epirubicin\, phase 2.\nStudy: Precise Chemoresection in Low-gra
 de NMIBC Using Drug Screens in Patient-derived Organoids\nEstimated primar
 y completion: 30 November 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/epirubicin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06227065
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981014-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Epirubicin: Phase 1/2 readout est. (NCT05981014)
DESCRIPTION:Epirubicin\, phase 1/2\, Breast Cancer.\nStudy: Study of Autolo
 gous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy 
 for HER2-Negative Breast Cancer\nEstimated primary completion: 31 December
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0598101
 4
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Epirubicin: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: A Clinical Study 
 of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With Breast Cance
 r (MK-2870-032)\nEstimated primary completion: 23 March 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06966700
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441460-9113@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20340807
DTEND;VALUE=DATE:20340808
SUMMARY:Epirubicin: Phase 3 readout est. (NCT07441460)
DESCRIPTION:Epirubicin\, phase 3\, Breast Cancer.\nStudy: A Phase III Study
  of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HE
 R2-Positive Breast Cancer\nEstimated primary completion: 7 August 2034. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/epirubicin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07441460
URL:https://assetmemo.bio/drug/epirubicin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
